Aura Biosciences launches public offering of common stock and pre-funded warrants to fund oncology therapies.

Aura Biosciences, a clinical-stage biotech company focused on precision therapies for solid tumors, announced a public offering of its common stock and pre-funded warrants. The offering includes an option for underwriters to buy additional shares and is subject to market conditions. Proceeds will support the development of Aura's lead candidate, bel-sar (AU-011), currently in late-stage trials for choroidal melanoma and early-stage trials for other cancers. The company aims to advance its oncology pipeline while preserving organ function in patients.